INTS Overview

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.

Wall Street analysts forecast INTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INTS is3.33 USD with a low forecast of 1.50 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Intensity Therapeutics Inc revenue for the last quarter amounts to -3.14M USD, decreased -1.97

Intensity Therapeutics Inc. EPS for the last quarter amounts to -2401000.00 USD, decreased -10.01

Intensity Therapeutics Inc (INTS) has 5 emplpoyees as of March 31 2026.

Today INTS has the market capitalization of 15.28M USD.